PDCD1 and nasopharyngeal carcinoma: This prospective phase 2 trial aims to assess the benefit of adding the anti-PD‐1 antibody nivolumab to standard induction chemotherapy in patients with EBV-positive NPC, with complete response rate after cisplatin/5-FU plus nivolumab induction as the primary endpoint.